[Cardiovascular side-effects of triptanes in migraine exist but are rare. 5-HT receptor mediated extracranial vasoconstriction is the most common cause].
Triptans, 5-HT1B/1D agonists used in migraine treatment, are rarely involved in serious coronary events due to vasospasm. 5 HT1 receptors mediate vasodilation and vasoconstriction of coronary arteries. Reports of serious coronary events mainly concern patients with known risk factors for coronary artery disease. It is prudent to obtain a thorough medical history before treatment with a triptan is started. If chest pain occurs, the possibility of coronary ischemia should be investigated. Stroke, a known complication to migraine, has also been reported in patients treated with triptans, but available data do not suggest that triptans, when correctly used, greatly increase the risk.
Hedenmalm
K
K
Klinisk farmakologi, biverkningssektionen, Läkemedelsverket, Uppsala. karin.hedenmalm@mpa.se
D000075202:Contraindications; D003327:Coronary Disease / Q000139:chemically induced*; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D009203:Myocardial Infarction / Q000139:chemically induced; D018570:Risk Assessment; D012307:Risk Factors; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000009:adverse effects*; D020521:Stroke / Q000139:chemically induced; D018170:Sumatriptan / Q000008:administration & dosage / Q000009:adverse effects; D014662:Vasoconstrictor Agents / Q000008:administration & dosage / Q000009:adverse effects*
D017366:Serotonin Receptor Agonists; D014662:Vasoconstrictor Agents; D018170:Sumatriptan